Literature DB >> 1366259

Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point.

L Hansson1, T Hedner, B Dahlöf.   

Abstract

A novel design for intervention studies is presented, the so called PROBE study (Prospective Randomized Open, Blinded End-point). This design is compared to the classical double-blind design. Among the advantages of the PROBE design are lower cost and greater similarity to standard clinical practice, which should make the results more easily applicable in routine medical care. Since end-points are evaluated by a blinded end-point committee it is obvious that there should be no difference between the two types of trials in this regard.

Mesh:

Substances:

Year:  1992        PMID: 1366259     DOI: 10.3109/08037059209077502

Source DB:  PubMed          Journal:  Blood Press        ISSN: 0803-7051            Impact factor:   2.835


  126 in total

Review 1.  Antihypertensive effects of aspirin: what is the evidence?

Authors:  Leonelo E Bautista; Lina M Vera
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

2.  High-dose atorvastatin versus usual-dose simvastatin for secondary prevention after myocardial infarction.

Authors:  Michael Clearfield
Journal:  Curr Atheroscler Rep       Date:  2007-01       Impact factor: 5.113

3.  Ceftriaxone and Cefotaxime Have Similar Effects on the Intestinal Microbiota in Human Volunteers Treated by Standard-Dose Regimens.

Authors:  Charles Burdet; Nathalie Grall; Morgane Linard; Antoine Bridier-Nahmias; Michèle Benhayoun; Khadija Bourabha; Mélanie Magnan; Olivier Clermont; Camille d'Humières; Olivier Tenaillon; Erick Denamur; Laurent Massias; Sarah Tubiana; Loubna Alavoine; Antoine Andremont; France Mentré; Xavier Duval
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

4.  Surgical Performance in Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation Phase III Clinical Trial.

Authors:  Maged D Fam; Daniel Hanley; Agnieszka Stadnik; Hussein A Zeineddine; Romuald Girard; Michael Jesselson; Ying Cao; Lynn Money; Nichol McBee; Amanda J Bistran-Hall; W Andrew Mould; Karen Lane; Paul J Camarata; Mario Zuccarello; Issam A Awad
Journal:  Neurosurgery       Date:  2017-11-01       Impact factor: 4.654

5.  A pragmatic, adaptive clinical trial design for a rare disease: The FOcal Cerebral Arteriopathy Steroid (FOCAS) trial.

Authors:  Yeonhee Park; Heather J Fullerton; Jordan J Elm
Journal:  Contemp Clin Trials       Date:  2019-10-13       Impact factor: 2.226

6.  Low-dose pravastatin and age-related differences in risk factors for cardiovascular disease in hypercholesterolaemic Japanese: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA study).

Authors:  Noriaki Nakaya; Kyoichi Mizuno; Yasuo Ohashi; Tamio Teramoto; Shinji Yokoyama; Katsumi Hirahara; Masahiro Mizutani; Haruo Nakamura
Journal:  Drugs Aging       Date:  2011-09-01       Impact factor: 3.923

7.  The Secondary Prevention of Small Subcortical Strokes (SPS3) study.

Authors:  Oscar R Benavente; Carole L White; Lesly Pearce; Pablo Pergola; Ana Roldan; Marie-France Benavente; Christopher Coffey; Leslie A McClure; Jeff M Szychowski; Robin Conwit; Patricia A Heberling; George Howard; Carlos Bazan; Gabriela Vidal-Pergola; Robert Talbert; Robert G Hart
Journal:  Int J Stroke       Date:  2011-01-26       Impact factor: 5.266

8.  Comparison between the effects of hydrochlorothiazide and indapamide on the kidney in hypertensive patients inadequately controlled with losartan.

Authors:  S Wang; J Li; X Zhou; K Liu; X Zhang; Q Meng; R Shi; D Shi; X Chen
Journal:  J Hum Hypertens       Date:  2017-07-13       Impact factor: 3.012

9.  INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study.

Authors:  Rhonda M Cooper-DeHoff; Eileen M Handberg; Giuseppe Mancia; Qian Zhou; Annette Champion; Udo F Legler; Carl J Pepine
Journal:  Expert Rev Cardiovasc Ther       Date:  2009-11

10.  Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipine.

Authors:  Roberto Fogari; Amedeo Mugellini; Paola Preti; Annalisa Zoppi; Giuseppe Derosa
Journal:  Vasc Health Risk Manag       Date:  2010-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.